Abstract
Cluster of differentiation 14 (CD14) is a glycoprotein essential to the immune system that is found primarily on monocytes, macrophages, and other immune cells. Despite its importance, there are no examples in the literature of small compounds that can substantially alter CD14 expression in human embryonic stem cells (hESCs) or fibroblasts. This study addresses this gap by exploring the potential of metadichol, a nanoemulsion of long-chain fatty alcohols, to induce CD14 expression in hESCs. Metadichol has been previously shown in our studies to express CD33 and CD34 as well as all the nuclear receptors and the family of sirtuins and Toll receptors. Using quantitative real-time PCR (qRT‒PCR) and Western blotting, we showed that metadichol significantly upregulated CD14 expression in hESCs (by seventeen-fold) but downregulated it in fibroblasts. This novel finding indicates that metadichol can modulate CD14 expression in a cell type-specific manner, highlighting its potential to enhance stem cell-based therapeutics and advance our understanding of stem cell biology. The implications of these findings are substantial, suggesting new directions for research into the immunomodulatory functions of hESCs and their potential applications in regenerative medicine. Our work highlights the potential of metadichol as a powerful tool for modulating CD14 expression in stem and somatic cells, marking a significant step forward in the field of stem cell research and therapy development.